NOVAN INC (NOVN) Stock Price & Overview
NASDAQ:NOVN • US66988N2053
Current stock price
The current stock price of NOVN is 0.0941 USD. Today NOVN is down by -24.84%. In the past month the price decreased by -77.43%. In the past year, price decreased by -96.77%.
NOVN Key Statistics
- Market Cap
- 2.636M
- P/E
- N/A
- Fwd P/E
- 0.58
- EPS (TTM)
- -1.51
- Dividend Yield
- N/A
NOVN Stock Performance
NOVN Stock Chart
NOVN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NOVN. When comparing the yearly performance of all stocks, NOVN is a bad performer in the overall market: 99.88% of all stocks are doing better.
NOVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NOVN. NOVN may be in some trouble as it scores bad on both profitability and health.
NOVN Earnings
NOVN Forecast & Estimates
7 analysts have analysed NOVN and the average price target is 15.81 USD. This implies a price increase of 16701.28% is expected in the next year compared to the current price of 0.0941.
For the next year, analysts expect an EPS growth of 78.75% and a revenue growth 19.34% for NOVN
NOVN Groups
Sector & Classification
NOVN Financial Highlights
Over the last trailing twelve months NOVN reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 21.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NOVN Ownership
NOVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.64 | 874.551B | ||
| JNJ | JOHNSON & JOHNSON | 20.47 | 580.403B | ||
| MRK | MERCK & CO. INC. | 23.05 | 298.788B | ||
| PFE | PFIZER INC | 9.08 | 158.307B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.11 | 120.824B | ||
| ZTS | ZOETIS INC | 16.5 | 49.921B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.07 | 27.297B | ||
| VTRS | VIATRIS INC | 5.25 | 15.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.67 | 11.345B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.682B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.091B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.46 | 4.345B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NOVN
Company Profile
Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. The company is headquartered in Durham, North Carolina and currently employs 89 full-time employees. The company went IPO on 2016-09-21. The firm is focused on developing and commercializing therapeutic products for skin diseases. The firm is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The firm's commercial portfolio includes six branded prescription drugs. The company actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.
Company Info
IPO: 2016-09-21
NOVAN INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA 27703 US
CEO: Paula Brown Stafford
Employees: 89
Phone: 19194858080.0
NOVAN INC / NOVN FAQ
Can you describe the business of NOVAN INC?
Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. The company is headquartered in Durham, North Carolina and currently employs 89 full-time employees. The company went IPO on 2016-09-21. The firm is focused on developing and commercializing therapeutic products for skin diseases. The firm is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The firm's commercial portfolio includes six branded prescription drugs. The company actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.
What is the current price of NOVN stock?
The current stock price of NOVN is 0.0941 USD. The price decreased by -24.84% in the last trading session.
What is the dividend status of NOVAN INC?
NOVN does not pay a dividend.
What is the ChartMill rating of NOVAN INC stock?
NOVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ex-dividend date for NOVN stock?
The next ex-dividend date for NOVAN INC (NOVN) is November 4, 2022.
Is NOVAN INC (NOVN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NOVN.
What is the next earnings date for NOVN stock?
NOVAN INC (NOVN) will report earnings on 2023-08-09, before the market open.